Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 441-445

  Ahmed, Ossama A ^a   Elsebaey, Mohamed A ^b   Fouad, Mohamed Hassan A ^a   Elashry, Heba ^c   Elshafie, Ahmed I ^a   Elhadidy, Ahmed A ^b   Esheba, Noha E ^b   Elnaggar, Mohammed H ^b   Soliman, Shaimaa ^d   Abd Elsalam, Sherief ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

^c TANTA UNIVERSITY   (Egypt)

^d MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Genotype 4; Hepatitis C virus; Sofosbuvir plus daclatasvir; Sustained virologic response

Indexed keywords

EID: 85044749548     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S160593     Document Type: Article

References (27)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
2. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012;19:560–567.
3. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014;39:137–147.
4. Elwan N, Elfert A, Abd-Elsalam S, et al. Study of hepatic steatosis index in patients with chronic HCV infection. Int J Curr Microbiol App Sci. 2016;5(5):266–274.
5. Ahmed OA, Kaisar HH, Hawash N, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets. 2017;17(2):95–100.
6. Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. Epub 2017;163:51–56.
7. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10: 553–562.
8. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9: 509–516.
9. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta analysis of observational studies. Ann Intern Med. 2013;158:329–337.
10. Pol S, Corouge M, vallet-Pichard A. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21–26.
11. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015;42:258–272.
12. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I. Daclatasvir plus sofosbuvir for previously treated or untreated chronic hCV infection. N Engl J Med. 2014;370:211–221.
13. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049–1054.
14. Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 hcv infection. J Hepatol. 2015;62 219–220.
15. El Raziky M, Gamil M, Hammad R, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: preliminary results from a phase IIa, partially randomised, open-label trial conducted in Egypt (OSIRIS). Hepatology. 2015;62:145.
16. Asselah T, Hassanein TI, Qaqish RB, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (Agate-I). Hepatology. 2015;62:119.
17. Asselah T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol. 2014;61:435–438.
18. Fontaine H, Hezode C, Zoulim F, et al. Efficacy of the oral sofosbuvir based combinations in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 Hepather. Abstract LP28 presented at: 50th Annual Meeting of European Association for the Study of the Liver; April 22–26, 2015; Vienna, Austria.
19. Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421–431.
20. Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol. 2015;63:1511–1522.
21. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmaco-genetics: state of the art in 2010. Hepatology. 2011;53:336–345.
22. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
23. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359.
24. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol. 2015;7(12):1617–1631.
25. Reid M, Price JC, Tien PC. Hepatitis C virus infection in the older patient. Infect Dis Clin N Am. 2017;31:827–838.
26. Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/ sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 year or older. Hepatology. 2016;63(4):1112–1119.
27. Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015–1022.